BRPI0507420A - composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência - Google Patents

composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência

Info

Publication number
BRPI0507420A
BRPI0507420A BRPI0507420-7A BRPI0507420A BRPI0507420A BR PI0507420 A BRPI0507420 A BR PI0507420A BR PI0507420 A BRPI0507420 A BR PI0507420A BR PI0507420 A BRPI0507420 A BR PI0507420A
Authority
BR
Brazil
Prior art keywords
antiflatulence
compositions
statin
starch
agent
Prior art date
Application number
BRPI0507420-7A
Other languages
English (en)
Inventor
Marta Guerrero
Anna Orriols
Manuel M Raga
Antonio Guglietta
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of BRPI0507420A publication Critical patent/BRPI0507420A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES HIPOCOLESTEROLêMICAS COMPREENDENDO UMA ESTATINA E UM AGENTE ANTIFLATULêNCIA A presente invenção refere-se às composições hipocolesterolêmicas compreendendo estatinas mais agentes antiflatulência. Especificamente, as composições da presente invenção compreendem uma estatina selecionada do grupo consistindo em atorvastatina, cerivastatina, fluvastatina, lovastatina, pituvastatina, rosuvastatina e sinvastatina, quer na forma ou como sais farmaceuticamente aceitáveis e hidratos das mesmas, mais um agente antiflatulência selecionado do grupo consistindo em simeticona e dimeticona. A combinação de estatinas mais agentes antiflatulência é útil na prevenção e gerenciamento da flatulência causada pelas estatinas.
BRPI0507420-7A 2004-02-03 2005-02-02 composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência BRPI0507420A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002317A EP1563837A1 (en) 2004-02-03 2004-02-03 Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
PCT/EP2005/001038 WO2005074915A1 (en) 2004-02-03 2005-02-02 Hypocholesterolemic compositions comprising a statin and an antiflatulent agent

Publications (1)

Publication Number Publication Date
BRPI0507420A true BRPI0507420A (pt) 2007-06-26

Family

ID=34684647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507420-7A BRPI0507420A (pt) 2004-02-03 2005-02-02 composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência

Country Status (15)

Country Link
US (1) US20080206328A1 (pt)
EP (2) EP1563837A1 (pt)
JP (1) JP2007520514A (pt)
KR (1) KR100815713B1 (pt)
CN (1) CN101094667A (pt)
AR (1) AR048668A1 (pt)
AU (1) AU2005210117A1 (pt)
BR (1) BRPI0507420A (pt)
CA (1) CA2556181A1 (pt)
NO (1) NO20063867L (pt)
PA (1) PA8622701A1 (pt)
PE (1) PE20050688A1 (pt)
TW (1) TW200529818A (pt)
UY (1) UY28729A1 (pt)
WO (1) WO2005074915A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1006879B (el) * 2005-09-14 2010-07-13 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
DK2018153T3 (da) 2006-04-26 2012-07-23 Rosemont Pharmaceuticals Ltd Flydende orale sammensætninger
EP1928425B1 (en) * 2006-05-12 2013-01-23 Pharmathen S.A. Pharmaceutical formulation containing fluvastatin
CN101229187B (zh) * 2007-01-23 2011-09-28 德国柏林化学股份有限公司 西甲硅油乳剂及其制备方法
CN104244946A (zh) * 2012-04-30 2014-12-24 霍夫曼-拉罗奇有限公司 新制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444764A (en) * 1979-08-06 1984-04-24 The Dow Chemical Company Phosphorus esters of alkylcycloalkyl-5-pyrimidinols and control of corn rootworm and western spotted cucumber beetle with them
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
DE3322770C2 (de) * 1983-06-24 1985-10-03 Deutsche Gesellschaft für Wiederaufarbeitung von Kernbrennstoffen mbH, 3000 Hannover Vorrichtung zur Handhabung und zum Schutz von Lagergebinden für radioaktive Stoffe
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
AU7218294A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations
WO2002009697A1 (en) * 2000-07-27 2002-02-07 Plus Chemicals, B.V Highly purified simvastatin compositions
EP1361867B1 (en) * 2001-02-22 2007-03-21 Jagotec AG Fibrate-statin combinations with reduced fed-fasted effects
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
MXPA04006780A (es) * 2002-01-11 2005-06-08 Athpharma Ltd Formulaciones farmaceuticas de pravastatina y metodos para usarlas.
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
EP1545503A4 (en) * 2002-09-03 2007-12-12 Circ Pharma Res And Dev Ltd PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATINES

Also Published As

Publication number Publication date
NO20063867L (no) 2006-10-26
CA2556181A1 (en) 2005-08-18
PE20050688A1 (es) 2005-10-14
AU2005210117A1 (en) 2005-08-18
WO2005074915A1 (en) 2005-08-18
TW200529818A (en) 2005-09-16
JP2007520514A (ja) 2007-07-26
EP1563837A1 (en) 2005-08-17
AR048668A1 (es) 2006-05-17
US20080206328A1 (en) 2008-08-28
CN101094667A (zh) 2007-12-26
EP1713469A1 (en) 2006-10-25
KR100815713B1 (ko) 2008-03-20
UY28729A1 (es) 2005-03-31
KR20060118579A (ko) 2006-11-23
PA8622701A1 (es) 2005-08-10

Similar Documents

Publication Publication Date Title
BRPI0507420A (pt) composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência
AR067030A2 (es) Composiciones farmaceuticas
HK1090295A1 (en) Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti- inflammatory, antithrombotic and antiplatelet activity
MX2007001553A (es) Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados.
WO2008045170A3 (en) Statin and omega-3 fatty acids for reduction of apo-b levels
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CR6687A (es) Composiciones farmaceuticas que comprenden inhibidoras de la hmg coa reductasa
RS51563B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ROOSUVASTATIN CALCIUM
ATE489093T1 (de) Heilmittel für hyperlipidämie
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
AR081032A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
JP2004537553A5 (pt)
AR074204A1 (es) Arilpiperazinas y su uso como antagonistas alfa -2c
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
DE60002769D1 (de) Wasserhaltiges, kristallines Calcium-Salz der Simvastatin Dihydroxy offene Säure
BR9813542A (pt) Combinações de estatina-éter carboxialquìlico
WO2006015171A3 (en) Use of glycosoaminoglycans for the prevention and treatment of sepsis
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
JP2013536408A5 (pt)
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
BRPI0417747A (pt) uso de compostos orgánicos
PE20081722A1 (es) Sal estroncio de atorvastatina y composicion farmaceutica que la incluye
CA2529367A1 (en) Preventing atrial fibrillation (af) with the use of statin drugs

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.